Literature DB >> 28264583

CRISPR-Mediated Knockout of Cybb in NSG Mice Establishes a Model of Chronic Granulomatous Disease for Human Stem-Cell Gene Therapy Transplants.

Colin L Sweeney1, Uimook Choi1, Chengyu Liu2, Sherry Koontz1, Seung-Kwon Ha3, Harry L Malech1.   

Abstract

Chronic granulomatous disease (CGD) is characterized by defects in the production of microbicidal reactive oxygen species (ROS) by phagocytes. Testing of gene and cell therapies for the treatment of CGD in human hematopoietic cells requires preclinical transplant models. The use of the lymphocyte-deficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse strain for human hematopoietic cell xenografts to test CGD therapies is complicated by the presence of functional mouse granulocytes capable of producing ROS for subsequent bacterial and fungal killing. To establish a phagocyte-defective mouse model of X-linked CGD (X-CGD) in NSG mice, clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 was utilized for targeted knockout of mouse Cybb on the X-chromosome by microinjection of NSG mouse zygotes with Cas9 mRNA and CRISPR single-guide RNA targeting Cybb exon 1 or exon 3. This resulted in a high incidence of indel formation at the CRISPR target site, with all mice exhibiting deletions in at least one Cybb allele based on sequence analysis of tail snip DNA. A female mouse heterozygous for a 235-bp deletion in Cybb exon 1 was bred to an NSG male to establish the X-CGD NSG mouse strain, NSG.Cybb[KO]. Resulting male offspring with the 235 bp deletion were found to be defective for production of ROS by neutrophils and other phagocytes, and demonstrated increased susceptibility to spontaneous bacterial and fungal infections with granulomatous inflammation. The establishment of the phagocyte-defective NSG.Cybb[KO] mouse model enables the in vivo assessment of gene and cell therapy strategies for treating CGD in human hematopoietic cell transplants without obfuscation by functional mouse phagocytes, and may also be useful for modeling other phagocyte disorders in humanized NSG mouse xenografts.

Entities:  

Keywords:  CRISPR/Cas9; Cybb; NSG mouse; chronic granulomatous disease; knockout

Mesh:

Substances:

Year:  2017        PMID: 28264583      PMCID: PMC5549813          DOI: 10.1089/hum.2017.005

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  25 in total

1.  Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease.

Authors:  I Barde; E Laurenti; S Verp; M Wiznerowicz; S Offner; A Viornery; A Galy; A Trumpp; D Trono
Journal:  Gene Ther       Date:  2011-05-05       Impact factor: 5.250

2.  Microhomology-based choice of Cas9 nuclease target sites.

Authors:  Sangsu Bae; Jiyeon Kweon; Heon Seok Kim; Jin-Soo Kim
Journal:  Nat Methods       Date:  2014-07       Impact factor: 28.547

3.  Generation of functionally mature neutrophils from induced pluripotent stem cells.

Authors:  Colin L Sweeney; Randall K Merling; Uimook Choi; Debra Long Priel; Douglas B Kuhns; Hongmei Wang; Harry L Malech
Journal:  Methods Mol Biol       Date:  2014

4.  Opportunistic bacterial infections in breeding colonies of the NSG mouse strain.

Authors:  O Foreman; A M Kavirayani; S M Griffey; R Reader; L D Shultz
Journal:  Vet Pathol       Date:  2010-09-03       Impact factor: 2.221

5.  CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease.

Authors:  Suk See De Ravin; Linhong Li; Xiaolin Wu; Uimook Choi; Cornell Allen; Sherry Koontz; Janet Lee; Narda Theobald-Whiting; Jessica Chu; Mary Garofalo; Colin Sweeney; Lela Kardava; Susan Moir; Angelia Viley; Pachai Natarajan; Ling Su; Douglas Kuhns; Kol A Zarember; Madhusudan V Peshwa; Harry L Malech
Journal:  Sci Transl Med       Date:  2017-01-11       Impact factor: 17.956

6.  Common severe infections in chronic granulomatous disease.

Authors:  Beatriz E Marciano; Christine Spalding; Alan Fitzgerald; Daphne Mann; Thomas Brown; Sharon Osgood; Lynne Yockey; Dirk N Darnell; Lisa Barnhart; Janine Daub; Lisa Boris; Amy P Rump; Victoria L Anderson; Carissa Haney; Douglas B Kuhns; Sergio D Rosenzweig; Corin Kelly; Adrian Zelazny; Tamika Mason; Suk See DeRavin; Elizabeth Kang; John I Gallin; Harry L Malech; Kenneth N Olivier; Gulbu Uzel; Alexandra F Freeman; Theo Heller; Christa S Zerbe; Steven M Holland
Journal:  Clin Infect Dis       Date:  2014-12-23       Impact factor: 9.079

7.  Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease.

Authors:  M C Dinauer; L L Li; H Björgvinsdóttir; C Ding; N Pech
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

8.  Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing.

Authors:  Ulrich Siler; Anna Paruzynski; Heidi Holtgreve-Grez; Elena Kuzmenko; Ulrike Koehl; Eleonore D Renner; Canan Alhan; Arjan A van de Loosdrecht; Joachim Schwäble; Thomas Pfluger; Joelle Tchinda; Markus Schmugge; Anna Jauch; Sonja Naundorf; Klaus Kühlcke; Gundula Notheis; Tayfun Güngor; Christof V Kalle; Manfred Schmidt; Manuel Grez; Reinhard Seger; Janine Reichenbach
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

9.  One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering.

Authors:  Haoyi Wang; Hui Yang; Chikdu S Shivalila; Meelad M Dawlaty; Albert W Cheng; Feng Zhang; Rudolf Jaenisch
Journal:  Cell       Date:  2013-05-02       Impact factor: 41.582

10.  Long-term high-level reconstitution of NADPH oxidase activity in murine X-linked chronic granulomatous disease using a bicistronic vector expressing gp91phox and a Delta LNGFR cell surface marker.

Authors:  Mohammed A Sadat; Nancy Pech; So Saulnier; Brendan A Leroy; Johann P Hossle; Manuel Grez; Mary C Dinauer
Journal:  Hum Gene Ther       Date:  2003-05-01       Impact factor: 5.695

View more
  5 in total

Review 1.  Advances and highlights in primary immunodeficiencies in 2017.

Authors:  Javier Chinen; Morton J Cowan
Journal:  J Allergy Clin Immunol       Date:  2018-08-29       Impact factor: 10.793

2.  Using CRISPR/Cas9 for Gene Knockout in Immunodeficient NSG Mice.

Authors:  Yubin Du; Wen Xie; Fan Zhang; Uimook Choi; Chengyu Liu; Colin L Sweeney
Journal:  Methods Mol Biol       Date:  2019

Review 3.  In vivo genome editing thrives with diversified CRISPR technologies.

Authors:  Xun Ma; Avery Sum-Yu Wong; Hei-Yin Tam; Samuel Yung-Kin Tsui; Dittman Lai-Shun Chung; Bo Feng
Journal:  Zool Res       Date:  2018-03-18

4.  Rapid generation of Col7a1-/- mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells.

Authors:  Beau R Webber; Kyle T O'Connor; Ron T McElmurry; Elise N Durgin; Cindy R Eide; Christopher J Lees; Megan J Riddle; Wendy E Mathews; Natasha Y Frank; Mark A Kluth; Christoph Ganss; Branden S Moriarity; Markus H Frank; Mark J Osborn; Jakub Tolar
Journal:  Lab Invest       Date:  2017-09-11       Impact factor: 5.662

5.  CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC.

Authors:  I Tirado-Gonzalez; E Czlonka; A Nevmerzhitskaya; D Soetopo; E Bergonzani; A Mahmoud; A Contreras; I Jeremias; U Platzbecker; J P Bourquin; U Kloz; F Van der Hoeven; H Medyouf
Journal:  Leukemia       Date:  2017-12-06       Impact factor: 11.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.